Literature DB >> 9793388

[Controlled cyclophotocoagulation].

P R Preussner1.   

Abstract

BACKGROUND: In the past, the main problem of transscleral cyclophotocoagulation was related to the energy dosage of the individual effect. Since the target tissue is not directly observable, no information about the coagulation process was available to the surgeon. High inter- and intraindividual variations of the tissue properties often led to under- or overdosage. Underdosage is therapeutically useless, while overdosage causes the so-called "popeffects" which may induce severe damage to the eye. SOLUTION: A small fraction of the impinging laser radiation passes the ciliary body after multiple scattering, is reflected from the fundus, leaves the eye through the optical media and can be recorded by a photodetector outside the eye. The time dependence of this detector signal directly monitors the change in transmission of the coagulated tissue, because all other parameters influencing the signal are constant in time. Using this information, the surgeon or a computer can interrupt the laser process. CLINICAL EVALUATION: In the eyes treated since September 1996, a mean reduction of intraocular pressure was achieved comparable to the values for uncontrolled cyclophotocoagulation reported in the literature. So far, no case of severe complications has been observed.
CONCLUSION: The accuracy and safety of transscleral cyclophotocoagulation are improved by this real-time control procedure. Reduction of risk may allow broader application of the method.

Entities:  

Mesh:

Year:  1998        PMID: 9793388     DOI: 10.1007/s003470050329

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  5 in total

1.  Real-time imaging of transscleral diode laser cyclophotocoagulation by optical coherence tomography.

Authors:  H Hoerauf; M Müller; G Hüttmann; C Winter; T Schlote
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-28       Impact factor: 3.117

2.  Controlled cyclophotocoagulation with the 940 nm laser for primary open angle glaucoma in African eyes.

Authors:  Paul-Rolf Preussner; Faustin Ngounou; Gabriel Kouogan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

Review 3.  [Controlled cyclophotocoagulation (COCO) : What needs to be considered?]

Authors:  P-R Preußner
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

4.  Two-year efficacy after first transscleral controlled cyclophotocoagulation in patients with and without pseudoexfoliation.

Authors:  Markus Lenzhofer; Melchior Hohensinn; Wolfgang Hitzl; Veit Steiner; Armin Motaabbed; Karolina Motloch; Hans Peter Colvin; Herbert A Reitsamer; Sarah Moussa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-02       Impact factor: 3.117

5.  MicroPulse Transscleral Laser Therapy Demonstrates Similar Efficacy with a Superior and More Favorable Safety Profile Compared to Continuous-Wave Transscleral Cyclophotocoagulation.

Authors:  Enrico Bernardi; Marc Töteberg-Harms
Journal:  J Ophthalmol       Date:  2022-02-08       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.